ERBB2 and breast cancer: The phase II WJOG9917B NEWBEAT trial (UMIN000030242), investigated the efficacy and safety of nivolumab in combination with paclitaxel and bevacizumab as a first-line therapy in 57 HER2-negative metastatic BC patients.